Therapeutic Advances in Medical Oncology
ISSN:1758-8340

Therapeutic Advances in Medical Oncology

THER ADV MED ONCOL
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:15 Weeks
新锐分区:医学2区
年发文量:228
影响因子:4.2
JCR分区:Q2

基本信息

《 医学 肿瘤 学 治疗 进展 》 是 一 本 开放 获取 、 同行 评审 期刊 , 提供 最 高 质量 的 文章 、 综述 和 学术 评论 , 介绍 癌症 医学 治疗 方面 的 开创 性 努力 和 创新 研究 。该 杂志 以 临床 和 药理 学 为 重点 , 面向 肿瘤 医学 的 临床 医生 和 研究 人员 , 为 发表 该 领域 最 高 质量 的 文章 提供 了 印刷 和 在线 论坛 。该 杂志 是 出版 伦理 委员 会 ( COPE ) 的 成员 。
1758-8340SCIE/Scopus收录/DOAJ开放期刊
4.2
3.9
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学2区
ONCOLOGY 肿瘤学
3区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:ONCOLOGY
SCIE
Q2
89/328
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:ONCOLOGY
SCIE
Q2
120/328
34
228
24%-15 WeeksUSD2800ONCOLOGY-
2.4%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
78.51%99.3%1.79%
CiteScore:6.60
SJR:1.549
SNIP:0.990
学科类别分区排名百分位
大类:Medicine
小类:Oncology
Q1
97 / 415

期刊高被引文献

HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919833519
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919862692
Clinically relevant drug interactions with multikinase inhibitors: a review
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835918818347
D-methionine alleviates cisplatin-induced mucositis by restoring the gut microbiota structure and improving intestinal inflammation
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835918821021
Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919850367
Current status of hepatocellular carcinoma detection: screening strategies and novel biomarkers
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919869120
Academic oncology clinicians’ understanding of biosimilars and information needed before prescribing
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835918818335
Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919846402
Late-line treatment in metastatic gastric cancer: today and tomorrow
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919867522
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919827714
New frontiers in the medical management of gastrointestinal stromal tumours
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919841946
Targeting the SLIT/ROBO pathway in tumor progression: molecular mechanisms and therapeutic perspectives
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919855238
Karonudib is a promising anticancer therapy in hepatocellular carcinoma
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919866960
SOX11: friend or foe in tumor prevention and carcinogenesis?
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919853449
Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919855491
Opportunities for cannabis in supportive care in cancer
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919866362
Results from a meta-analysis of immune checkpoint inhibitors in first-line renal cancer patients: does PD-L1 matter?
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919861905
Novel therapeutic avenues in triple-negative breast cancer: PI3K/AKT inhibition, androgen receptor blockade, and beyond
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919880429
Neoadjuvant therapy of locally/regionally advanced melanoma
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919866959
The endonuclease APE1 processes miR-92b formation, thereby regulating expression of the tumor suppressor LDLR in cervical cancer cells
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919855859
Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919846375
Gelsolin-like actin-capping protein has prognostic value and promotes tumorigenesis and epithelial-mesenchymal transition via the Hippo signaling pathway in human bladder cancer
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919841235
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919874653
From guidelines to clinical practice: a roadmap for oncologists for nutrition therapy for cancer patients
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919880084
The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919875549
The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919850665
Microwave ablation versus resection for hepatocellular carcinoma within the Milan criteria: a propensity-score analysis
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919874652
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919871126
Cytoreductive nephrectomy in the current treatment algorithm
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919879026
KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919885540
FAM84B promotes prostate tumorigenesis through a network alteration
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919846372
Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919833864
The risk of liver cancer in autoimmune liver diseases
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919861914
Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919874650
Ratio of carcinoembryonic antigen in pleural fluid and serum for the diagnosis of malignant pleural effusion
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919850341
High-CLDN4 ESCC cells harbor stem-like properties and indicate for poor concurrent chemoradiation therapy response in esophageal squamous cell carcinoma
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919875324
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919891652
CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919853193
Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919853971
Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919842438
Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy?
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919833863
Novel multi-drugs incorporating hybrid-structured nanofibers enhance alkylating agent activity in malignant gliomas
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919875555
Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919864850
Major innovations and clinical applications of disodium-levofolinate: a review of available preclinical and clinical data
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919853954
The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: a systematic review and meta-analysis
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919855235
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919891608
Regorafenib in glioblastoma recurrence: how to deal with conflicting ‘real-life’ experiences?
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919887667
Corrigendum to Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919871363
The effect of CELLFOODTM on radiotherapy or combined chemoradiotherapy: preclinical evidence
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919878347
TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection
来源期刊:Therapeutic Advances in Medical OncologyDOI:10.1177/1758835919897543

相关文章

2026年3月发布
大类学科小类学科Top期刊综述期刊
医学2区
ONCOLOGY 肿瘤学
3区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学2区
ONCOLOGY 肿瘤学
3区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学2区
ONCOLOGY 肿瘤学
3区